After a successful postdoc at the Ontario Cancer Institute, where he developed a proprietary platform for the discovery of
novel cancer
therapeutic agents, Bray was asked to join the former Amgen Research Institute in Toronto (now called the Advanced Medical Discovery Institute and no longer part of the parent company) as the head of their quantitative biology group and
act as liaison to Amgen Inc. in California.